Alzheimer Disease/Dementia

The US FDA Fast Track status advances remlifanserin for Alzheimer disease psychosis, with phase 2 RADIANT data expected in fall 2026.

Once-weekly subcutaneous lecanemab matched IV initiation exposure in early Alzheimer disease, but comparative clinical outcome data remain limited.

Mander highlights sleep as a modifiable dementia risk factor, emphasizing sleep apnea diagnosis and treatment to support brain health.

Emerging data link sleep disorder severity to Alzheimer's biomarker accumulation, with small CPAP studies suggesting partial biomarker reversibility with treatment.

The FDA approved dextromethorphan hydrobromide-bupropion hydrochloride for agitation associated with dementia due to Alzheimer disease.

Older adults with both anemia and elevated neurofilament light chain levels faced a more than 3.5-fold increased risk of developing dementia.

Episode highlights include a new AD blood test for PCPs, sleep effects of elinzanetant among postmenopausal women, lung cancer screening gains, and more.

Your daily dose of the clinical news you may have missed.

New data highlight digital dementia risk scores, plasma p-tau217 prediction, and patient-centered endpoints in Alzheimer disease research.

Booster-backed speed-of-processing brain training links to lower Alzheimer disease and dementia diagnoses, suggesting modest computer exercises may delay decline.

Clevenger explains how better recognition of agitation in Alzheimer disease, and stronger caregiver–clinician communication, can meaningfully improve outcomes.

This episode reviews intranasal epinephrine use, pediatric atopic dermatitis data, dementia screening tools, adolescent TMS, and oral PCSK9 therapy.

New data from the DROP-AD study suggests that dried blood spots could revolutionize screening approaches for clinical trials.

Your daily dose of the clinical news you may have missed.

The FDA has accepted a supplemental NDA for AXS-05 for agitation associated with Alzheimer disease and granted Priority Review, with a PDUFA action date of April 30, 2026.

Take a quick look back at developments this year with our higlights of acceleration of DMTs, particularly focusing on anti-amyloid antibodies and novel oral agents.

A multidisciplinary panel of neurologists, geriatricians, and researchers examined how early identification, equitable access, and value-based models could reshape Alzheimer disease care.

Missed endpoints in midstage tau trials are reshaping the Alzheimer pipeline, with growing focus on inflammatory and vascular pathways. Review them here.

Findings highlight an AI-based machine-learning approach designed to work around incomplete diagnostic labeling in Alzheimer disease using routine clinical data.

Clevenger speaks to primary care clinicians, emphasizing 3 priorities: engage family as partners, ask about agitation, and recognize its danger to patient and caregiver.

Blood-based monitoring could enable earlier intervention as approximately 20% of initially negative participants transitioned to positive biomarker status.

CTAD 2025: Early, continued treatment with lecanemab may delay Alzheimer disease progression by up to 8.3 years; SC dosing demonstrates bioequivalence.

The phase 3 results offer key lessons for metabolic and inflammatory pathway targets, ADDF notes, highlighting biomarker findings that advance Alzheimer science.

Clevenger, a professor of nursing at Emory University, shares practical strategies to manage agitation in Alzheimer disease, emphasizing that this symptom is treatable.

Semaglutide did not slow AD progression in phase 3 evoke trials. UK and US experts express disappointment but laud value of outcomes to continuing research.